Search results
Results from the WOW.Com Content Network
On 11 December 2008, a panel of experts convened by the FDA voted to ban [vague] drugs Serevent and Foradil from use in the treatment of asthma. When these two drugs are used without steroids, they increase the risks of more severe attacks. They said that two other, much more popular, asthma drugs containing long-acting β agonists—Advair and ...
Here’s a fun fact: Ninety percent of people with asthma will develop symptoms of exercise-induced asthma as well, but 10 percent of people with this condition (also referred to as exercise ...
Zafirlukast is FDA-approved for the prevention and treatment of asthma in adults and children older than 5 years old. [1] Like other leukotriene receptor antagonists, zafirlukast is thought to be useful for the long-term treatment of asthma, but it is generally less effective than inhaled glucocorticoids as monotherapy (which are the standard of care) or long-acting beta-2 agonists in ...
The goal of asthmatic agents is to reduce asthma exacerbation frequencies and related hospital visits. Anti-asthmatic agents as rescue medications for acute asthma attacks include short-acting β 2-adrenergic receptor agonists (SABA), short-acting muscarinic antagonists (SAMA), systemic glucocorticoids, and magnesium sulfate.
Aspirin-exacerbated respiratory disease (AERD), also called NSAID-exacerbated respiratory disease (N-ERD) or historically aspirin-induced asthma and Samter's Triad, is a long-term disease defined by three simultaneous symptoms: asthma, chronic rhinosinusitis with nasal polyps, and intolerance of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs).
Levosalbutamol's bronchodilator properties give it indications in treatment of COPD (chronic obstructive pulmonary disease, also known as chronic obstructive lung disease) and asthma. Like other bronchodilators, it acts by relaxing smooth muscle in the bronchial tubes , and thus shortening or reversing an acute "attack" of shortness of breath ...
Nucala, known also as mepolizumab, was first approved in 2015 for a type of severe asthma in the United States. Its sales grew 18% to 1.7 billion pounds in 2023. It contributed nearly 6% to GSK ...
Budesonide/formoterol, sold under the brand name Symbicort among others, is a fixed-dose combination medication used in the management of asthma or chronic obstructive pulmonary disease (COPD). [2] It contains budesonide , a steroid ; and formoterol , a long-acting β 2 -agonist (LABA). [ 2 ]